Compare Snap Inc (SNAP) vs TG Therapeutics Inc (TGTX) Price & Performance

Snap Inc. (SNAP) trades at $5.285, down 1.03% over 24 hours, near its analyst low target of $5.25. The stock shows a bullish technical signal with strong moving average support, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $5.93B in 2025 with a narrowing net loss of -$460M, while Q2 2026 earnings beat expectations with 19% revenue growth. Cash flow from operations improved to $656M in 2025, signaling operational strength amid persistent losses.

Outlook remains cautious with a consensus price target of $7.02, implying 33% upside, but risks include high debt, negative profitability, and competitive pressures. Institutional sentiment is mixed with 38% buy ratings, yet insider selling and a recent downgrade to strong sell highlight volatility. Investment opportunity hinges on sustained ad revenue growth and path to profitability, balanced against execution risks in a challenging digital ad market.

TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.

Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.